Corresponding animal experiments also showed that baicalin has the potential to reverse HFD-induced hyperglycemia and systemic insulin resistance in mice, which might be attributed to the activation of the AKT/AKT substrate of 160 kD (AS160)/GLUT4 and MAPK/PPARγ coactivator 1α (PGC-1α)/GLUT4 pathways [83]. The gene discussed is AKT1; the disease is Hyperglycemia.